A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapies
Chemotherapy-induced nausea and vomiting (CINV) affects up to 80 % of cancer patients, significantly impacts the health in terms of their quality of life and straining healthcare resources. CINV is categorized into anticipatory, acute, and delayed types. Risk factors include younger age, female sex,...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294225000747 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849387091902857216 |
|---|---|
| author | Derangula Lavanya VelugotlaPranathi Prasanna Asma Firdous Sneha Thakur |
| author_facet | Derangula Lavanya VelugotlaPranathi Prasanna Asma Firdous Sneha Thakur |
| author_sort | Derangula Lavanya |
| collection | DOAJ |
| description | Chemotherapy-induced nausea and vomiting (CINV) affects up to 80 % of cancer patients, significantly impacts the health in terms of their quality of life and straining healthcare resources. CINV is categorized into anticipatory, acute, and delayed types. Risk factors include younger age, female sex, a history of CINV, and the emetogenic potential of the chemotherapy agents. Drugs like cisplatin and anthracycline-cyclophosphamide combinations are highly emetogenic and pose the greatest risk. Advances in managing CINV include evidence-based guidelines and the use of antiemetic medications such as 5-HT3 receptor antagonists, NK-1 receptor antagonists, and corticosteroids. These measures have reduced vomiting incidents, but complete control of nausea remains challenging. Up to 60 % of patients still experience delayed nausea, and anticipatory nausea and vomiting affect up to 30 % and 20 % of patients, respectively, by the fourth treatment cycle. Clinical and alternative therapies are though effective, research suggests integrated management for CINV. Tailored approach is needed as it has both psychological and physiological influence. To overcome the challenges, the guidelines and antiemetic regimens should be improved according to individual patient evaluation and awareness is necessary. Research is ongoing to develop targeted therapies that combine pharmacological and behavioral interventions to improve CINV management, especially for patients who do not respond well to current antiemetic treatments. |
| format | Article |
| id | doaj-art-8a1cf46e45984b37a5de3c02e3fcd688 |
| institution | Kabale University |
| issn | 2468-2942 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj-art-8a1cf46e45984b37a5de3c02e3fcd6882025-08-20T03:55:22ZengElsevierCancer Treatment and Research Communications2468-29422025-01-014410093810.1016/j.ctarc.2025.100938A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapiesDerangula Lavanya0VelugotlaPranathi Prasanna1Asma Firdous2Sneha Thakur3Pharm-D, St. Paul's college of Pharmacy, Hyderabad, IndiaPharm-D, St. Paul's college of Pharmacy, Hyderabad, IndiaPharm-D, St. Paul's college of Pharmacy, Hyderabad, IndiaAssociate Professor, Head of Department, Department of Pharmacognosy, St. Pauls College of Pharmacy Hyderabad, India; Corresponding author: Associate Professor & Head, Department of Pharmacognosy, St. Pauls college of Pharmacy.Chemotherapy-induced nausea and vomiting (CINV) affects up to 80 % of cancer patients, significantly impacts the health in terms of their quality of life and straining healthcare resources. CINV is categorized into anticipatory, acute, and delayed types. Risk factors include younger age, female sex, a history of CINV, and the emetogenic potential of the chemotherapy agents. Drugs like cisplatin and anthracycline-cyclophosphamide combinations are highly emetogenic and pose the greatest risk. Advances in managing CINV include evidence-based guidelines and the use of antiemetic medications such as 5-HT3 receptor antagonists, NK-1 receptor antagonists, and corticosteroids. These measures have reduced vomiting incidents, but complete control of nausea remains challenging. Up to 60 % of patients still experience delayed nausea, and anticipatory nausea and vomiting affect up to 30 % and 20 % of patients, respectively, by the fourth treatment cycle. Clinical and alternative therapies are though effective, research suggests integrated management for CINV. Tailored approach is needed as it has both psychological and physiological influence. To overcome the challenges, the guidelines and antiemetic regimens should be improved according to individual patient evaluation and awareness is necessary. Research is ongoing to develop targeted therapies that combine pharmacological and behavioral interventions to improve CINV management, especially for patients who do not respond well to current antiemetic treatments.http://www.sciencedirect.com/science/article/pii/S2468294225000747Chemotherapy-induced nauseaQuality of lifeIncidence ratesRisk factorsManagement strategiesAntiemetic agents |
| spellingShingle | Derangula Lavanya VelugotlaPranathi Prasanna Asma Firdous Sneha Thakur A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapies Cancer Treatment and Research Communications Chemotherapy-induced nausea Quality of life Incidence rates Risk factors Management strategies Antiemetic agents |
| title | A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapies |
| title_full | A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapies |
| title_fullStr | A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapies |
| title_full_unstemmed | A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapies |
| title_short | A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapies |
| title_sort | systemic review on chemotherapy induced nausea and vomiting risk and clinical management with alternative therapies |
| topic | Chemotherapy-induced nausea Quality of life Incidence rates Risk factors Management strategies Antiemetic agents |
| url | http://www.sciencedirect.com/science/article/pii/S2468294225000747 |
| work_keys_str_mv | AT derangulalavanya asystemicreviewonchemotherapyinducednauseaandvomitingriskandclinicalmanagementwithalternativetherapies AT velugotlapranathiprasanna asystemicreviewonchemotherapyinducednauseaandvomitingriskandclinicalmanagementwithalternativetherapies AT asmafirdous asystemicreviewonchemotherapyinducednauseaandvomitingriskandclinicalmanagementwithalternativetherapies AT snehathakur asystemicreviewonchemotherapyinducednauseaandvomitingriskandclinicalmanagementwithalternativetherapies AT derangulalavanya systemicreviewonchemotherapyinducednauseaandvomitingriskandclinicalmanagementwithalternativetherapies AT velugotlapranathiprasanna systemicreviewonchemotherapyinducednauseaandvomitingriskandclinicalmanagementwithalternativetherapies AT asmafirdous systemicreviewonchemotherapyinducednauseaandvomitingriskandclinicalmanagementwithalternativetherapies AT snehathakur systemicreviewonchemotherapyinducednauseaandvomitingriskandclinicalmanagementwithalternativetherapies |